|Chemaphor Receives First U.S. Order For Oximunol (tm) Chewables|
OTTAWA, ONTARIO, April 19, 2012 - Avivagen Animal Health Inc., the commercial arm of Chemaphor Inc. (TSXV:CFR), is pleased to announce that it has received the first order for Oximunol(TM) Chewables for dogs for the veterinary market in the U.S. This follows on from the recent announcement of its distribution agreement for Oximunol(TM) Chewable Tablets in the U.S. and accreditation from the National Animal Supplement Council of Oximunol(TM) companion animal supplement products in the U.S. David Hankinson, CEO of Chemaphor, said "This achievement of an order for product is a major milestone in Chemaphor's strategy to expand into the International market with products that can improve the quality of life for companion animals. We are pleased by the size of this first purchase order and are excited that Oximunol(TM) Chewable Tablets, which has been so well-received by dog owners in the Canadian market, finally will become available to dog owners in the US through their veterinarians." Dave Hankinson also added, "This is a great first step in our international commercial efforts and brings our investors validation of demand for our Oximunol(TM) Chewables, while we seek distribution agreements in other territories and also aim to bring follow-on products to market."
About Oximunol(TM) Chewables - Optimized health in a chewable tablet
Oximunol(TM) is a scientifically formulated chewable tablet that contains Chemaphor's proprietary, patented active ingredient OxC-beta. OxC-beta is a highly concentrated version of oxidized derivatives of carotenoids that are found naturally and extensively in the plant world in minute amounts. It is currently available for dogs of all ages. Oximunol(TM) Chewables work with a dog's own immune system to optimize overall health and well-being, including:
+Promotes and supports healthy joint function
+Promotes and maintains normal mobility
+Enhances healthy condition of skin and coat
+May help discomfort associated with normal daily activity
+Leads to maintenance of normal intestinal function
Chemaphor, a wellness company, is committed to developing and delivering products for animals and humans to assist in optimizing health and daily quality of life. Chemaphor is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at www.chemaphor.com.
Avivagen, a wholly-owned subsidiary of Chemaphor, is dedicated to improving the quality of life of animals through science-based, natural health products proven in clinical trials. More information can be found at www.avivagen.com.
Forward Looking Statements This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Chemaphor Inc. and Avivagen Animal Health Inc. and the environment in which their respective businesses operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Chemaphor Inc. and Avivagen Animal Health Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Chemaphor assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements. The results of treatment described above are based on historical results. Different animals may experience different results from the treatments described above.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information:
David Hankinson Graham Burton, PhD
CEO, Chemaphor Inc. President and Co-Founder, Chemaphor Inc.
Phone: 902-825-9270 Phone: 613-990-0969